Donate today and get a Marketplace mug -- perfect for all your liquid assets! Donate now
COVID-19

Safe, effective COVID-19 vaccine may not arrive until April 2021 or later

David Brancaccio, Nova Safo, Candace Manriquez Wrenn, and Alex Schroeder Oct 6, 2020
Heard on:
HTML EMBED:
COPY
Noel Celis/AFP via Getty Images
COVID-19

Safe, effective COVID-19 vaccine may not arrive until April 2021 or later

David Brancaccio, Nova Safo, Candace Manriquez Wrenn, and Alex Schroeder Oct 6, 2020
Heard on:
Noel Celis/AFP via Getty Images
HTML EMBED:
COPY

According to news reports, the FDA wanted new, stricter rules for coronavirus vaccines but that the White House blocked this, saying there was no medical reason. The tougher rules regulators wanted very likely would have meant no vaccine approvals before the election.

And there’s a new global analysis suggesting the first approved vaccines might not come until later still, perhaps next spring. Marketplace’s Nova Safo has the latest, and he spoke with “Marketplace Morning Report” host David Brancaccio. The following is an edited transcript of their conversation.

David Brancaccio: Where is this estimate of a vaccine timeline coming from and what does it say specifically?

Nova Safo: It’s coming from a group that takes a more global view of the pandemic and is looking at stringent vaccine approval standards. The Center for Global Development, which is a think tank, did some mathematical modeling and combined that with expert interviews. It came up with a 50% chance of at least one vaccine by April of next year — a vaccine that’s deemed safe and effective. It says there’s an 85% chance of a vaccine by end of 2021.

I spoke this morning with Anthony McDonnell, senior policy analyst at the Center for Global Development, about why it will take that long.

Anthony McDonnell: It takes a very long time to collect data on the 30,000-plus people that you need to run through clinical trial. And if you want to have six months worth of safety data on your vaccine, you need to vaccinate people and wait for six months.

Safo: The New York Times says that the FDA wants a two-month median follow-up time for current trials. That’s reportedly not been approved yet.

Brancaccio: We know that vaccine approval is just the first step — there’s a logistics operation that comes after. How long is manufacturing enough vaccines for everyone projected to take?

Safo: McDonnell told me there is enough vaccine manufacturing capacity globally. But there is a catch.

McDonnell: The slow thing is that you have to redesign factories such that they can make these products and that can take up to a year, 18 months before you get factories ready to start making vaccines at really large scale.

Safo: He says if we get multiple vaccines approved, that could speed up production.

Brancaccio: Is there modeling on how a longer timeline for a vaccine might impact the economy?

Safo: For that we turn to the Organization for Economic Cooperation and Development — it’s assuming that there won’t be widespread deployment of a vaccine until the end of next year, and with that, expects the global economy to grow by 5% and the U.S. economy to grow by 4%. That won’t take us back to the pre-pandemic trajectory we were on, but it’s better than previously forecast.

There’s a lot happening in the world.  Through it all, Marketplace is here for you. 

You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible. 

Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.